Pharmaceutical

Meitheal gains rights to CONTEPO from Nabriva in North America

Meitheal Pharmaceuticals has gained rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics for the North American region.

Jul 20, 2024 - 04:00
Meitheal gains rights to CONTEPO from Nabriva in North America
Meitheal Pharmaceuticals has gained rights to CONTEPO (fosfomycin for injection) from Nabriva Therapeutics for the North American region.
Read the original article

Tags:

Previous Article

Rona Therapeutics gains Series A+ funds for siRNA pipeline expansion

Next Article

EMA accepts Deciphera’s MAA cell tumour treatment for review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

IGC Pharma signs agreement to adopt AI solutions into drug discovery

IGC Pharma signs agreement to adopt AI solutions into d...

Nov 22, 2023

STAT+: Medicare’s new pay boost for primary care is angering specialists

STAT+: Medicare’s new pay boost for primary care is ang...

Nov 11, 2023

STAT+: How biotech deal-making really works behind the scenes, according to founders

STAT+: How biotech deal-making really works behind the ...

Oct 20, 2023